Business Context and Reporting Period
This Form 8-K Current Report was filed by Syndax Pharmaceuticals, Inc. on September 26, 2018, covering events occurring on September 24 and September 25, 2018. The company is an emerging growth company focused on pharmaceutical development, specifically reporting updates regarding its clinical trials and corporate governance.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance changes and clinical trial updates.
Material Changes
- Board Resignations: Henry Chen and Luke Evnin, Ph.D., resigned from the Board of Directors effective September 25, 2018. The resignations were not due to any disagreements with the Company regarding operations, policies, or practices.
- Board Appointments: The Board appointed Jennifer Jarrett and William Meury as new directors effective September 25, 2018, to fill the vacancies. Ms. Jarrett was appointed to the Nominating and Corporate Governance Committee, and Mr. Meury to the Audit Committee. Both are designated as Class II members serving until the 2021 annual meeting.
- Compensation Arrangements: New directors will receive annual cash compensation of $40,000 for Board service, plus committee-specific fees ($4,000 for Ms. Jarrett; $8,500 for Mr. Meury). Each received an initial one-time option to purchase 35,000 shares of common stock, vesting monthly over three years.
- Clinical Trial Update: The Company issued a press release updating guidance regarding the Phase 3 registration trial (E2112) of entinostat plus exemestane for advanced HR+, HER2- breast cancer.
Guidance, Outlook, and Risks
The filing references an update to guidance concerning the Phase 3 registration trial of entinostat plus exemestane (Study E2112). The specific details of the updated guidance, including enrollment targets or timeline adjustments, are contained in the attached press release (Exhibit 99.2) and are not detailed within the text of this Form 8-K. No new risks or contingencies were explicitly described in the body of this report beyond the standard disclosure of the trial update.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.2) for specific details on the updated guidance for the entinostat Phase 3 trial (E2112).
- Verify the background and qualifications of new directors Jennifer Jarrett and William Meury.
- Confirm the impact of the Board composition changes on the Audit and Nominating Committees.
- Monitor future filings for the vesting schedule and exercise of the 35,000 share options granted to the new directors.